FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313280156> ?p ?o ?g. }

• W4313280156 endingPage "454" @default.
• W4313280156 startingPage "447" @default.
• W4313280156 abstract "Background Fremanezumab is a humanized monoclonal antibody against calcitonin gene-related peptide for subcutaneous use to suppress migraine attacks. A phase 3 study was conducted to investigate the safety of autoinjector (AI)-assisted self-injection of fremanezumab 225 mg.Research Design and Methods The multicenter, open-label study involving 71 patients with migraine was conducted between June 2020 and November 2020 at ten institutions in Japan. The study consisted of a 4-week (28-day) screening period and an 8-week (57-day) treatment period. According to the investigator’s instructions, all patients successfully performed self-injection for 4 weeks at the institutional site and at home and maintained eDiaries of their headaches. The primary endpoint was safety of the drug based on treatment-emergent adverse events (TEAEs).Results Treatment-emergent adverse events were more frequent after at-home injection than after at-site injection, but they were mainly injection site reactions and mostly mild. The safety profile was comparable, raising no concerns compared with what has been reported in previous studies. Both migraine days and headache days were decreased considerably.Conclusions Overall, AI-assisted, at-home self-injection of fremanezumab was found to be generally safe and well-tolerated. This injection strategy is considered clinically meaningful in view of improved utility of and adherence to the drug." @default.
• W4313280156 created "2023-01-06" @default.
• W4313280156 creator A5015453063 @default.
• W4313280156 creator A5015541790 @default.
• W4313280156 creator A5037141327 @default.
• W4313280156 creator A5040134238 @default.
• W4313280156 creator A5045845843 @default.
• W4313280156 creator A5049170963 @default.
• W4313280156 creator A5065666450 @default.
• W4313280156 creator A5074470251 @default.
• W4313280156 creator A5077638637 @default.
• W4313280156 creator A5086871788 @default.
• W4313280156 date "2022-12-28" @default.
• W4313280156 modified "2023-09-26" @default.
• W4313280156 title "A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home" @default.
• W4313280156 cites W1891579824 @default.
• W4313280156 cites W2004916007 @default.
• W4313280156 cites W2012715161 @default.
• W4313280156 cites W2020568108 @default.
• W4313280156 cites W2026462640 @default.
• W4313280156 cites W2047455969 @default.
• W4313280156 cites W2120236823 @default.
• W4313280156 cites W2148083007 @default.
• W4313280156 cites W2158846562 @default.
• W4313280156 cites W2768357559 @default.
• W4313280156 cites W2801085490 @default.
• W4313280156 cites W2803715733 @default.
• W4313280156 cites W2916512992 @default.
• W4313280156 cites W3046802458 @default.
• W4313280156 cites W3084814300 @default.
• W4313280156 cites W3120040964 @default.
• W4313280156 cites W3185467542 @default.
• W4313280156 cites W3195126616 @default.
• W4313280156 cites W3206572053 @default.
• W4313280156 cites W4214697113 @default.
• W4313280156 cites W574772692 @default.
• W4313280156 cites W73775937 @default.
• W4313280156 doi "https://doi.org/10.1080/14740338.2023.2162038" @default.
• W4313280156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36578197" @default.
• W4313280156 hasPublicationYear "2022" @default.
• W4313280156 type Work @default.
• W4313280156 citedByCount "1" @default.
• W4313280156 countsByYear W43132801562023 @default.
• W4313280156 crossrefType "journal-article" @default.
• W4313280156 hasAuthorship W4313280156A5015453063 @default.
• W4313280156 hasAuthorship W4313280156A5015541790 @default.
• W4313280156 hasAuthorship W4313280156A5037141327 @default.
• W4313280156 hasAuthorship W4313280156A5040134238 @default.
• W4313280156 hasAuthorship W4313280156A5045845843 @default.
• W4313280156 hasAuthorship W4313280156A5049170963 @default.
• W4313280156 hasAuthorship W4313280156A5065666450 @default.
• W4313280156 hasAuthorship W4313280156A5074470251 @default.
• W4313280156 hasAuthorship W4313280156A5077638637 @default.
• W4313280156 hasAuthorship W4313280156A5086871788 @default.
• W4313280156 hasBestOaLocation W43132801561 @default.
• W4313280156 hasConcept C118303440 @default.
• W4313280156 hasConcept C126322002 @default.
• W4313280156 hasConcept C141071460 @default.
• W4313280156 hasConcept C163170386 @default.
• W4313280156 hasConcept C168563851 @default.
• W4313280156 hasConcept C170493617 @default.
• W4313280156 hasConcept C197934379 @default.
• W4313280156 hasConcept C203092338 @default.
• W4313280156 hasConcept C2776390293 @default.
• W4313280156 hasConcept C2778541695 @default.
• W4313280156 hasConcept C2780966972 @default.
• W4313280156 hasConcept C2992435398 @default.
• W4313280156 hasConcept C3018125106 @default.
• W4313280156 hasConcept C3018380316 @default.
• W4313280156 hasConcept C31760486 @default.
• W4313280156 hasConcept C42219234 @default.
• W4313280156 hasConcept C535046627 @default.
• W4313280156 hasConcept C57658597 @default.
• W4313280156 hasConcept C71924100 @default.
• W4313280156 hasConceptScore W4313280156C118303440 @default.
• W4313280156 hasConceptScore W4313280156C126322002 @default.
• W4313280156 hasConceptScore W4313280156C141071460 @default.
• W4313280156 hasConceptScore W4313280156C163170386 @default.
• W4313280156 hasConceptScore W4313280156C168563851 @default.
• W4313280156 hasConceptScore W4313280156C170493617 @default.
• W4313280156 hasConceptScore W4313280156C197934379 @default.
• W4313280156 hasConceptScore W4313280156C203092338 @default.
• W4313280156 hasConceptScore W4313280156C2776390293 @default.
• W4313280156 hasConceptScore W4313280156C2778541695 @default.
• W4313280156 hasConceptScore W4313280156C2780966972 @default.
• W4313280156 hasConceptScore W4313280156C2992435398 @default.
• W4313280156 hasConceptScore W4313280156C3018125106 @default.
• W4313280156 hasConceptScore W4313280156C3018380316 @default.
• W4313280156 hasConceptScore W4313280156C31760486 @default.
• W4313280156 hasConceptScore W4313280156C42219234 @default.
• W4313280156 hasConceptScore W4313280156C535046627 @default.
• W4313280156 hasConceptScore W4313280156C57658597 @default.
• W4313280156 hasConceptScore W4313280156C71924100 @default.
• W4313280156 hasIssue "6" @default.
• W4313280156 hasLocation W43132801561 @default.
• W4313280156 hasLocation W43132801562 @default.
• W4313280156 hasOpenAccess W4313280156 @default.
• W4313280156 hasPrimaryLocation W43132801561 @default.

• next